|Security||WSCI / WSI Industries, Inc. (92932Q102)|
|President and CEO||PUDIL MICHAEL J|
|Industry||Metalworking Machinery And Equipment|
|Institutional Shares||342,868 - 11.54%|
|Common Shares Outstanding||2,970,283 shares (as of 2018-05-27)|
|Institutional Value||$ 1,507,000 USD|
Institutional Stock Ownership and Shareholders
WSI Industries, Inc. (NASDAQ:WSCI) has 11 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 342,868 shares.
Largest shareholders include
BlackRock Institutional Trust Company, N.A., BlackRock Inc., Renaissance Technologies LLC, Bank Of America Corp /de/, Panagora Asset Management Inc, Deutsche Bank Ag\, BlackRock Fund Advisors, Acadian Asset Management Llc, UBS Group AG, and Morgan Stanley.
WSI Industries, Inc. (NASDAQ:WSCI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|BANK OF AMERICA CORP /DE/||6,003||6,000||-0.05||30||31||3.33|
|Renaissance Technologies LLC||106,100||520|
|ACADIAN ASSET MANAGEMENT LLC||1,285||1,285||0.00||7||7||0.00|
|PANAGORA ASSET MANAGEMENT INC||4,449||4,349||-2.25||22||23||4.55|
|ROYAL BANK OF CANADA||607||0||-100.00||3||0||-100.00|
|UBS Group AG||0||1,200||0||6|
|DEUTSCHE BANK AG\||4,886||4,300||-11.99||23||22||-4.35|
|BlackRock Fund Advisors||1,036||1,576||52.12||4||5||25.00|
|WELLS FARGO & COMPANY/MN||0||1||0||0|
|BlackRock Institutional Trust Company, N.A.||109,494||109,494||0.00||402||328||-18.41|
18h - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
Related News Stories
Welcome everybody. We are about to begin the webinar first quarter 2018 financial review. Before we do so we will start with the Safe Harbor Statement and then I will turn the meeting over to Mr. Milton Todd Ault III, CEO and Chairman of the Board of DPW Holdings as well as Will Horne, CFO of DPW Holdings. (40-2)
Digital Power Corporation (NYSEMKT:DPW) Fourth Quarter and Full Year 2017 Financial Review Conference Call April 17, 2018 6:30 PM ET (40-6)
as of ET